The QualityStocks Daily Monday, July 16th, 2018

Today's Top 3 StockMarketWatch

MarketClub Analysis (MDGS) +300.00%

NetworkNewsWire (FDMSF) +28.04%

QualityStocks (GRBX) +27.96%

The QualityStocks Daily Stock List

GT Biopharma, Inc. (GTBP)

Stockhouse, Stockopedia, InvestorsHub, Insider Financial, and OTC Markets reported on GT Biopharma, Inc. (GTBP), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

GT Biopharma, Inc. centers on unique drugs for the treatment of cancer and CNS diseases (Neurology and Pain), along with other unmet medical needs. Its lead oncology drug candidate is OXS-1550 (DT2219ARL). The Company owns the worldwide rights to commercialize OXS-1550. GT Biopharma is based in Tampa, Florida.

GT Biopharma is targeting multiple myeloma, triple-negative breast cancer, non-Hodgkin’s lymphoma, and more. It is doing so with highly potent biopharmaceutical drugs designed for targeted therapy. The Company’s current CNS pipeline products include treatment for neuropathic pain, the symptoms of myasthenia gravis, and motion sickness.

GT Biopharma’s CNS platform focuses on acquiring or discovering and patenting late-stage, de-risked, and close-to-market improved treatments for CNS diseases. Furthermore, the CNS platform focuses on guiding the products through the Food and Drug Administration (FDA) approval process to the NDA.

The Company’s OXS-1550 is an ADC (Antibody Drug Conjugate) drug. What makes OXS-1550 (DT2219ARL) different from other treatments, such as chemotherapy, is that the design of it is to specifically target and kill cancer cells while reducing damage to normal tissues.

OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of cytotoxic payload.

The OXS-3550 TriKE technology was developed by researchers at the University of Minnesota Masonic Cancer Center. This targeted immunotherapy directs immune cells to kill cancer cells while lessening drug-related toxicity.

GT Biopharma announced this past April that the Proof-of-Concept clinical trial with GTP-011 that was started in late February 2018 is totally enrolled. The study is a single-blind, placebo-controlled, cross-over study. The main objective of the study will be to demonstrate the anti-motion sickness efficacy of transdermal GTP-011, which is a novel treatment for the symptoms of motion sickness.

Last month, GT Biopharma announced preliminary clinical data taken from an interim review of the OXS-1550 Phase 1/2 trial following a Bi-Specific Antibody Drug Conjugate (ADC) Advisory Board meeting and follow up discussions. OXS-1550 targets cancer cells expressing the CD19 receptor, the CD22 receptor or both receptors.

OXS-1550 is undergoing evaluation in an open-label, two-stage, investigator-led, Phase 1/2 trial at the Masonic Cancer Center, University of Minnesota. The trial has two arms including patients diagnosed with relapsed/refractory B-cell lymphomas (NHL) and leukemias (ALL).

Eighteen patients have been enrolled to date (as of June 11, 2018). This includes 12 NHL and six ALL patients. At the time of the interim review, 13 patients met the evaluation criteria, including nine NHL and four ALL patients.

Clinical benefit was observed in over 50 percent of patients that met evaluation criteria. Efficacy signal was most pronounced in relapsed/refractory acute lymphocytic leukemia patients (ALL) with clinical benefit in 75 percent (three of four) of evaluable patients. Adverse events are largely grade 1 or 2 and reversible.

This month, GT Biopharma announced the promotion of Dr. Raymond W. Urbanski MD, PhD, to the position of Chief Executive Officer and Chairman of the Board effective immediately. Dr. Urbanski joined GT Biopharma in September of 2017 as the Chief Medical Officer (CMO). He was promoted to President and CMO on May 5, 2018.

GT Biopharma, Inc. (GTBP), closed Monday's trading session at $2.00, up 17.65%, on 71,499 volume with 161 trades. The average volume for the last 60 days is 60,856 and the stock's 52-week low/high is $1.19/$36.90.


Asia Equity Exchange Group, Inc. (AEEX)

OTC Markets, InvestorsHub, Morningstar, Simply Wall St, Stockhouse, Market Exclusive, 4-Traders, Super Stocks Screener, and MarketWatch reported on Asia Equity Exchange Group, Inc. (AEEX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Asia Equity Exchange Group, Inc. is working to establish and build an equity information service platform designed to provide equity investment financing information to all enterprises in the nations and regions of Asia. The Company, with its website, invested and operated by Asian Equity Exchange Group Co., Ltd., is an intercontinental equity exchange. It is also a service platform for companies in Asia to release equity investment and financing information.

Asia Equity Exchange Group successfully entered into the U.S. capital markets in November 2013. The Company has offices in Kowloon Bay, Hong Kong; Shenzhen, China; and New York, New York.

The operating structure of the Company is: Asia Equity Exchange Group, Inc. 100 percent shareholding Asian Equity Exchange Group Co. Ltd. 100 percent shareholding AEEX (HK) International Financial Services Limited 100 percent shareholding Asian & American Consultant (Shenzhen) Co. Ltd.

Asia Equity Exchange Group integrates worldwide capital and works with providers of a broad array of services. The Company provides growing and innovative companies with diversified and professional services, and global professional investors with quality, open, and diverse investment opportunities.

The Company serves as a significant part and a vital link of the multi-layered capital markets in Asia. Asia Equity Exchange Group enables companies to obtain the resources to successfully launch their IPO (Initial Public Offering).

Asia Equity Exchange Group helps companies develop in a sustainable manner. It also introduces high-value investment markets to professional institutional and individual investors. In addition, the Company aims to create a unique and authoritative intercontinental equity information platform, which effectively complements business functions, service means and financing channels with OTC markets in different nations and regions.

Asia Equity Exchange Group is also working to build a system of intercontinental cooperation to provide listed enterprises with equity financing means through domestic and out of the country channels, and to provide nurturing, pre-listing tutoring, and incubating, as well as supporting services for their listing on overseas capital markets by shifting boards. The Company can provide the referral of third-party professional service providers, including Legal Counselling, PCAOB auditors and other related agencies, required for international listing to members.

Recently, Asia Equity Exchange Group announced that 17 new member companies were approved and successfully listed on the Company's equity information disclosure platform, AEEx.  Also, four companies signed an "International Listing Consulting Agreement" with AEEX during Q1 of the 2018 fiscal year.

Mr. Xiangyu Wang, Chief Executive Officer of Asia Equity Exchange Group, said, "We believe the recent Chinese government initiatives in Hong Kong and mainland China promoting the development of public markets along with a greater interest among executives in public financial markets have contributed to a heightened demand for our online AEEx platform and exceptional consulting services. Moreover, we believe our platform raises awareness among the international community of the operations of Chinese enterprises through our centralized and standardized information services."  


Asia Equity Exchange Group, Inc. (AEEX), closed Monday's trading session at $4.86, up 0.21%, on 3,000 volume with 1 trade. The average volume for the last 60 days is 1,632 and the stock's 52-week low/high is $3.21/$21.11.


BioSig Technologies, Inc. (BSGM)

DreamTeamNetwork, Goldman Small Cap Research, PennyStockLocks, Stock Commander, SeeThruEquityResearch, Stock News Now, Wall Street Resources, Pumps and Dumps, The Wall Street Transcript, ResearchOTC, StockRockandRoll, and BUYINS.NET reported earlier on BioSig Technologies, Inc. (BSGM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BioSig Technologies, Inc. is a medical device company developing PURE EP™. This is a proprietary technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures. BioSig Technologies has its headquarters in Los Angeles, California focused on research and development (R&D).

The Company’s objective is to seek Food and Drug Administration (FDA) 510(k) approval for the PURE EP™ System. It is preparing to commercialize the PURE EP™ System. BioSig Technologies announced this past March that it filed a 510(k) application to the FDA for its first product, the PURE EP™ System.

The PURE EP™ is a next-generation surface electrocardiogram and intracardiac multichannel signal acquisition and analysis system. The design of it is to help electrophysiologists in making clinical decisions in real-time through acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data that may be used to guide the electrophysiologists in identifying ablation targets (areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia)).

BioSig Technologies has achieved proof of concept validation and tested its prototype at the University of California at Los Angeles (UCLA) Cardiac Arrhythmia Center. It has performed pre-clinical studies at the Mayo Clinic in Minnesota.

The Company is also collaborating with other prestigious cardiac arrhythmia centers. These include Texas Cardiac Arrhythmia Institute, UH Case Medical Center in Cleveland, Ohio, and Mount Sinai Medical Center in New York.

In addition, BioSig Technologies has expressed its plan to enter the developing field of bioelectric medicine. Additionally, the Company has partnered with Minnetronix on technology development. BioSig Technologies is working toward FDA 510(k) clearance and CE Mark for the PURE EP System.

Recently, BioSig Technologies announced that Mr. Sim Farar, Los Angeles based businessman and political adviser, joined the Advisory Board of the Company. Mr. Farar brings to BioSig Technologies more than three decades of experience in public and private sectors. From 1999 – 2000, following Presidential appointment and confirmation by the U.S. Senate, Mr. Farar served as the United States Representative to the 54th General Assembly at the United Nations.

BioSig Technologies also recently announced that its submission entitled, “Unipolar Intracardiac Signal Morphology as a Parameter for Catheter Contact Evaluation” was accepted as a 1-page paper for presentation at the 40th International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC 2018). The IEEE Engineering in Medicine and Biology Society is hosting its 40th International Engineering in Medicine and Biology Conference in Honolulu, Hawaii from July 17-21, 2018 at the Hawaii Convention Center.

BioSig Technologies, Inc. (BSGM), closed Monday's trading session at $2.17, up 0.93%, on 53,845 volume with 73 trades. The average volume for the last 60 days is 105,062 and the stock's 52-week low/high is $1.25/$2.609.


ImageWare Systems, Inc. (IWSY)

Microcapmillionaires, Pennybuster, PennyStocks24, Wall Street Daily, Greenbackers, Wall Street Resources, and TaglichBrothers reported on ImageWare Systems, Inc. (IWSY), and we also report on the Company, here at the QualityStocks Daily Newsletter.

ImageWare Systems, Inc. is a foremost developer of mobile and cloud-based multi-modal biometric identity management solutions, providing biometric, secure credential, and law enforcement technologies. Its biometric product line is scalable for worldwide deployment. ImageWare Systems has its corporate headquarters in San Diego, California. The Company lists on the OTC Markets’ OTCQB.

ImageWare Systems’ biometric product line includes a multi-biometric engine. This engine is hardware and algorithm independent. This allows the enrolment and management of unlimited population sizes.

The Company’s next-generation cloud identity management and authentication service is GoMobile Interactive™ (GMI). GMI is a cloud-based, multi-modal biometric mobile identity management solution. GMI is constructed upon the award-winning IWS Biometric Engine® (IWS BE), an SOA based server platform that enables advanced biometric data process and management with ESB connectivity.

ImageWare Systems has its is a highly modular, SOA-based software platform. It delivers a first-rate capability to quickly develop and deploy highly secure, yet flexible standards-based identity solutions.

Additionally, ImageWare has its EPI Builder®. This provides the basis for a multi-modal biometric capture platform, which ensures device interoperability and support for centralized and distributed deployment models. Products also include IWS Biometric Engine®. This is the first and only truly multi-modal, device-and algorithm-independent biometric software platform.

The Company also has its GoVerifyID solution. GoVerifyID is its patented mobile biometric user authentication solution. GoVerifyID technology provides turnkey solutions to secure enterprise systems from security infrastructure providers.

ImageWare Systems also has its GoVerifyID® Enterprise Suite. This is an innovative, multi-modal, multi-factor biometric authentication solution for the enterprise market. GoVerifyID Enterprise Suite is an algorithm-agnostic solution.

Recently, ImageWare Systems reported financial results for Q1 ended March 31, 2018. Revenue for Q1 ended March 31, 2018 decreased 23 percent to $716,000 from $928,000 in Q1 2017. Gross Profit for Q1 was $468,000 (65 percent) versus $666,000 (72 percent) in Q1 2017. Net Loss was $3.6 million in Q1 versus $2.7 million in Q1 2017.

Mr. Jim Miller, Chairman and Chief Executive Officer of ImageWare Systems, said, “Revenues in the quarter continued to reflect primarily our legacy business. However, we did see initial orders from several of our sales partners. Thus far in 2018 we have seen our first sales, although modest, under that model from our partners CDW, Fujitsu, Extenua and Avatier…”

ImageWare Systems, Inc. (IWSY), closed Monday's trading session at $1.20, up 6.19%, on 40,441 volume with 45 trades. The average volume for the last 60 days is 109,481 and the stock's 52-week low/high is $0.89/$2.24.


Wize Pharma, Inc. (WIZP)

Stockhouse, InvestorsHub, OTC Markets, Barchart, MarketWatch, Stockwatch, InsiderMole, Stockopedia, 4-Traders, and CapitalCube reported on Wize Pharma, Inc. (WIZP), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Wize Pharma, Inc. focuses on the treatment of ophthalmic disorders. This includes dry eye syndrome (DES). The Company previously went by the name Star Night Technologies Ltd. It changed its name to Wize Pharma, Inc. in July of 2015. The Company is headquartered in Hod Hasharon, Israel. A clinical-stage biopharmaceutical enterprise, Wize Pharma lists on the OTC Markets Group’s OTCQB.

The Company has in-licensed certain rights to purchase, market, sell and distribute a formula named LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including conjunctivochalasis (CCH) and Sjögren's Syndrome.

Currently, LO2A is registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES and CCH, and in the Netherlands for the treatment of DES and Sjögren's Syndrome.

At present, Wize Pharma is conducting a Phase II trial of LO2A for patients with CCH and a Phase IV study for LO2A for DES in patients with Sjögren's. Wize Pharma announced this past March that it enrolled the initial patient in its Phase IV clinical trial in Israel for LO2A in the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren's syndrome.

The randomized, double-masked study will evaluate LO2A in comparison to Alcon's Systane® Ultra UD, an over-the-counter (OTC) lubricant eye drop product used to relieve dry and irritated eyes. The design of the study (in addition to meeting marketing approval requirements in Israel) is to support Wize Pharma’s clinical approval pathway for LO2A for the treatment of DES in patients with Sjögren's in other markets including the U.S., China, and Ukraine.

LO2A is already approved in Israel for the treatment of DES. The expectation is that sales will start in Israel this year.

Wize Pharma announced in April that it completed enrolment of all 62 patients in its multi-center Phase II clinical trial in Israel of LO2A for the treatment of patients with moderate to severe Conjunctivochalasis (CCH). The current Phase II multi-center, randomized, double-blind, placebo-controlled clinical trial is evaluating the efficacy and safety of LO2A in comparison to placebo in patients with CCH.

Recently, Wize Pharma announced that it signed an exclusive distribution agreement with HPGC Medical Co., Ltd. for the distribution in China by HPGC of the formula LO2A. HPGC is a division of Harbin Pharmaceutical Group Co. Ltd., one of China's largest healthcare companies with 20,000 employees and assets worth $2.9 billion.

With this agreement, Wize Pharma assigned to HPGC the exclusive rights to distribute LO2A in China for the indications of DES, CCH, and Sjögren's. HPGC is responsible for obtaining regulatory approval for LO2A in China, and all costs associated with clinical trials, if needed, as well as registration fees.

Wize Pharma, Inc. (WIZP), closed Monday's trading session at $5.99, down 1.80%, on 22,074 volume with 38 trades. The average volume for the last 60 days is 1,749 and the stock's 52-week low/high is $3.00/$6.10.


Graphene 3D Lab, Inc. (GPHBF)

Agora Financial, OTC Markets, and Stockhouse reported on Graphene 3D Lab, Inc. (GPHBF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Graphene 3D Lab, Inc., by way of its wholly-owned subsidiary, Graphene Laboratories, Inc., develops, manufactures, and markets proprietary graphene-based nanocomposite materials for diverse types of 3D printing. This includes fused filament fabrication. Additionally, the Company engages in the manufacture and sale of graphene materials and nanocomposite enhanced polymers via Graphene Laboratories. Graphene is a single-layer of carbon atoms. Graphene is considered a wonder-material for its high strength, conductivity, as well as ultra-light-weight.

Listed on the OTCQB, Graphene 3D Lab is headquartered in Calverton, New York. The Company’s facility is also in Calverton. This facility is equipped with material processing and analytical equipment. The Company’s go-to-market product is Conductive Graphene Filament. Graphene 3D Lab has its Industrial Materials Division to commercialize graphene composite materials.

Graphene 3D Lab also engages in the design, manufacture, and marketing of 3D printers and related products for domestic and global customers. The Company centers on the development and commercialization of technologies, which improve the capabilities of 3D printing.

Its 3D printing division provides a suite of specialty fused fabrication filaments. Also, Graphene 3D Lab owns a new proprietary technology covering the preparation and separation of graphene's atomic layers.

Conductive Graphene Filament brings users the ability to 3D print circuitry and sensors for electronic applications. Graphene 3D Lab introduced a new functional magnetic filament to its product line in 2016. The new filament was developed by Graphene 3D. It enables printing of 3D projects with components that are attracted to magnetic fields. The Company said that the filament is ideal for producing sensors and mechanical actuators and motors by additive manufacturing.

Graphene 3D Lab announced earlier this year the commercial release of two new additions to the G6-Epoxy™ product line of advanced adhesive materials. This product line includes innovative carbon-silver adhesive materials that are built on technology, which has undergone development by its Industrial Division. The new epoxies are highly electrically conductive adhesives with a proprietary formula based on the combination of graphene and silver fillers and other additives.

The Company and AzTrong, Inc. (AzT) announced this past June the signing of a Memorandum of Understanding (MoU). This MoU outlines the terms of the Strategic Alliance Agreement to be executed forthcoming. The aim of the Alliance is to capitalize on Graphene 3D Lab’s extensive base of customers and wide-ranging Intellectual Property (IP) portfolio in the graphene sector.

AzT will contribute its large-scale manufacturing base with well-developed infrastructure in the U.S. and Taiwan. The desired outcome is cost-effective production of performance-improving graphene-based products with a focus on the energy storage, construction, automotive, and defense sectors.

Graphene 3D Lab has released the Graphene-HIPS 3D Printing Filament. Graphene-HIPS is a distinctly engineered and unique semi-flexible FDM 3D Printing material reinforced with graphene. The design of it is for high performance 3D printing. The FDM material exhibits first-rate interlayer adhesion, toughness, and premier impact resistance.

At the end of July 2017, Graphene 3D Lab announced that Mr. Roman Rabinovich was appointed to the Board of Directors, effective immediately. He serves as a Senior Director at FTI Consulting. Mr. Rabinovich has considerable experience in strategic development, transaction advisory, litigation support, and business restructuring engagements. His specialty is analysis of corporate finance and building optimal pricing strategies to improve sales growth.

Graphene 3D Lab, Inc. (GPHBF), closed Monday's trading session at $0.102, up 8.51%, on 23,993 volume with 13 trades. The average volume for the last 60 days is 56,179 and the stock's 52-week low/high is $0.07/$0.2141.


Aerpio Pharmaceuticals, Inc. (ARPO)

OTC Markets, HotStockCafe, HighRisingStocks, Street Insider, OTC Stock Picks, and MarketWatch reported on Aerpio Pharmaceuticals, Inc. (ARPO), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

A biopharmaceutical company, Aerpio Pharmaceuticals, Inc. centers on first-in-class treatments for ocular diseases. The Company’s lead compound is AKB‐9778. This is a small molecule activator of the Tie2 pathway. It is in clinical development for the treatment of non-proliferative diabetic retinopathy. Aerpio Pharmaceuticals has its headquarters in Cincinnati, Ohio.

At present, AKB-9778 is in a Phase 2b study (TIME-2b) for the treatment of non-proliferative diabetic retinopathy (NPDR). This is a disease that affects millions of people worldwide. Diabetic Retinopathy (DR) is a complication of diabetes caused by damage to blood vessels in the retina. AKB-9778 is undergoing development as a subcutaneous injection.

In addition, the Company’s second program in development builds on its unique approach to targeting the Tie2 pathway. ARP-1536 is a humanized monoclonal antibody. It works by binding the extracellular domain of VE-PTP, inhibiting its ability to interact with the Tie2 receptor. This prevents the inactivation of Tie2. It also promotes vascular stability.

ARP-1536 is in pre-clinical development. Aerpio Pharmaceuticals’ plan is to develop ARP-1536 in combination with anti-VEGF therapy for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME).

Furthermore, Aerpio’s AKB-4924 is in Phase 1 clinical development. The Company’s plan is to develop it as a once-daily, oral treatment for inflammatory bowel disease (IBD). AKB-4924 is an innovative small molecule inhibitor of prolyl-hydroxylase domain enzymes (PHDs).

PHDs are important regulators of hypoxia inducible factor-1 alpha (HIF-1 alpha) that, when dysregulated, has been shown to worsen inflammation and disrupt intestinal epithelial barrier function. Through inhibiting PHDs, AKB-4924 stabilizes HIF-1 alpha. This leads to resolution of inflammation and restoration of epithelial barrier function.

In August of this year, Aerpio Pharmaceuticals reported financial results for Q2 ended June 30, 2017. Q2 2017 financial highlights include research and development (R&D) expenses of $3.1 million for Q2 of 2017, versus $2.9 million for the same period the year prior.

General and administrative expenses were $2.4 million for Q2 of 2017, versus $1.5 million for the same period in 2016. As of June 30, 2017, cash and cash equivalents totaled $29.8 million.

Aerpio Pharmaceuticals, Inc. (ARPO), closed Monday's trading session at $4.19, up 0.96%, on 113,810 volume. The average volume for the last 60 days is 57,713 and the stock's 52-week low/high is $3.29/$6.75.


Heliospectra AB (publ) (HLSPY) reported previously on Heliospectra AB (HLSPY), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Heliospectra AB (publ) specializes in intelligent lighting technology for plant research and greenhouse cultivation. The Company designs, develops, manufactures, and sells lighting systems in Sweden and internationally. Heliospectra is a worldwide leader in intelligent lighting technology for horticulture controlled environments. OTCQB-listed, Heliospectra is headquartered in Gothenburg, Sweden.

The Company’s lighting system provides an effective and durable technology for cultivating greenhouse and indoor plants through uniting numerous diverse groups of versatile Light Emitting Diodes (LEDs) with optics, remote sensing techniques, and a strong heat dissipation solution. The Company provides smarter LED grow lights for commercial greenhouses, indoor grow facilities, as well as research applications.

The design and engineering of Heliospectra’s highly-engineered Heliospectra Light System is to replace traditional lighting solutions in commercial greenhouse environments. For indoor grow facilities, its patented lighting system enables an operation to grow plants, which look and taste better, have a longer shelf life, and boost the overall yield of its operation.

The Company’s patented solution enables growers to create customized lighting spectrum recipes. These recipes may be able to shorten a cannabis plant’s flowering cycle and even alter a strain’s balance of active cannabinoids.

Heliospectra’s LED light systems make it possible to closely control the intensity of light wavelengths and to accurately match the spectrum to a particular plant. The spectral distribution of its systems (400nm to 735nm) is consistent with the action spectrum of photosynthesis and vital photomorphological receptors.

The Company’s LX60 Series has been third-party verified as one of the most efficient and versatile on the market. It has efficiency equal to a 1,000 W HID, with only half the energy use.

Heliospectra’s E60 Series is a fixed spectrum, high intensity LED grow light fixture. The Plug-and-Play nature of the E60 provides immediate light. The fixture provides growers with quality light for horticulture crop production all year round.

Heliospectra has its new CORTEX light control software. Integrating with the Company’s intelligent LED lights and a light sensor, CORTEX provides commercial growers the industry's most advanced controls and automated schedules for supplemental light.

This week, Heliospectra announced an order from Medical 420, a medicinal cannabis cultivation facility in Macedonia. The indoor controlled environment facility is investing in Heliospectra LED lighting solutions to improve quality, speed up harvest cycles, and increase yields. The order is valued at $117,000 USD (984,000 SEK).

Medical 420 is setting up a new vertical cultivation facility in Macedonia. It has selected Heliospectra's intense E60 series as sole-source lighting. The E60 was developed together with some of the world's foremost commercial growers. The lamp has an optimized spectrum.

Heliospectra AB (HLSPY), closed Monday's trading session at $1.05, up 1.05%, on 10,299 volume with 16 trades. The average volume for the last 60 days is 7,211 and the stock's 52-week low/high is $0.4267/$1.20.


NexOptic Technology Corp. (NXOPF)

Stockhouse, InvestorsHub, Equedia, and MarketWatch reported on NexOptic Technology Corp. (NXOPF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

NexOptic Technology Corp. has an option to acquire, in the aggregate, 100 percent of Spectrum Optix, Inc., a private corporation (Calgary, Alberta). Essentially, at this time, the Companies are working as a single corporation; with their respective Chief Executive Officers (CEOs) sitting on each other's Boards of Directors. Spectrum Optix is developing technologies relating to imagery and light concentration applications. NexOptic Technology lists on the OTC Markets Group’s OTCQB. The Company is based in Vancouver, British Columbia.

Employing Blade Optics™, Spectrum Optix’s set of patent-pending optical technologies, Spectrum aims to increase aperture sizes within given depth constraints of various imaging and non-imaging optical applications. The two Companies believe that Blade Optics™ has the potential to breakdown many of the limitations associated with conventional, curved lens stacks.

Earlier in 2017, Spectrum Optix completed its proof-of-concept digital telescope prototype (POC). It uses a patent-pending Blade Optics™ technology, other optical elements, as well as electronic components. The intention of this prototype is to demonstrate the marketable features of Spectrum's Blade Optics™ technology and its potential to serve as a platform to be utilized in different optical applications.

This past June, NexOptic Technology and Spectrum Optix announced that, further to their joint news release dated April 4, 2017, they have successfully completed the engineering trade study of a new telephoto lens stack design intended for mobile devices, including smartphones. Spectrum Optix filed a patent application with the United States Patent and Trademark Office (USPTO) related to its new design. Completion of the engineering trade study is the initial step in the Companies' plan to grow their optical technology pipeline.

Last month, NexOptic Technology and Spectrum Optix announced that NexOptic satisfied all of the cash expenditure requirements under its option to acquire 100 percent ownership interest of Spectrum Optix pursuant to the agreement between NexOptic, Spectrum, and Spectrum's shareholders dated October 22, 2015. NexOptic Technology further announced that its plan is to exercise its final option and complete the acquisition of Spectrum Optix on or about October 2017.

Upon completion of this Agreement, key management members of Spectrum Optix and NexOptic Technology will be appointed to the senior management and Board of Director positions of NexOptic Technology. NexOptic’s patent-pending optical technologies and lens stack designs are scalable to diverse sizes. They can be manufactured utilizing readily available optical materials.

NexOptic Technology Corp. (NXOPF), closed Monday's trading session at $0.744, up 4.30%, on 1,000 volume with 1 trade. The average volume for the last 60 days is 28,238 and the stock's 52-week low/high is $0.6676/$1.21.


Alexandria Minerals Corp. (ALXDF)

TradingView, MarketWatch, and OTC Markets reported on Alexandria Minerals Corp. (ALXDF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Alexandria Minerals Corp. is a junior gold exploration and development company headquartered in Toronto, Ontario. It has strategic properties situated in the world-class mining districts of Val d'Or, Quebec; Red Lake, Ontario; and Snow Lake-Flin Flon, Manitoba. The Company’s focus is on its flagship property, the large Cadillac Break Property package in Val d'Or, Quebec. Alexandria Minerals’ shares trade on the OTC Markets Group’s OTCQB.

The Cadillac Break Property hosts important, near-surface, gold resources along the prolific, gold-producing Cadillac Break, all of which have considerable growth potential.

The Company’s strategic partnerships are: Agnico-Eagle Mines Limited 9 percent Owners; Teck 2 percent; IAMGOLD Corp., 2 percent; and Funds/High Net Worth Investors 50 percent. Alexandria Minerals’ worldwide gold resources are: Measured and Indicated: 1,400,000 ounces Au; Inferred: 939,200 ounces Au.

Alexandria Minerals has an aggressive exploration program to substantially grow its gold assets. It discovered the Province of Quebec’s next gold mine. In 2014, it sold the West Zone Au-Cu deposit to Agnico Eagle for $5M plus 2 percent NSR and Agnico Eagle filed the environmental application.

Alexandria Minerals had an aggressive exploration program on the Val d’Or Property. It was a 12,500-meter Drill Program. Furthermore, 41,500 meters are planned for completion in April of 2018.

Alexandria Minerals has signed an Option Agreement with Golden Valley Mines. This enables Alexandria to earn 80 percent in the Centremaque Property, located close to its Zone 4 drilling activities. The claims are a strategic addition to the Company’s wholly-owned western Cadillac Break Property Package in Val d'Or, Quebec.

Last week, Alexandria Minerals announced the assay results from 10 holes completed in its detailed summer drill program at Orenada Zone 4 near Val d’Or, Quebec. The reported results further confirm strong gold mineralization east of the Zone 4 open pit over a 250m strike length. The results expand high grade gold mineralization east beyond the limits of the 2009 resource estimate.

Mr. Eric Owens, Alexandria Minerals’ President and Chief Executive Officer, stated, “These exciting results emphasize potential for both growth and grade at Zone 4. We are finding a very robust core area that extends 1,100 metres along strike, down to 300 metres at depth and continues to be open in all directions. Our ongoing geologic and resource modelling efforts are being confirmed and strengthened as results come in. With assay results pending for 70 holes, we expect further great results for the rest of the year.”

Alexandria Minerals Corp. (ALXDF), closed Monday's trading session at $0.035, up 16.67%, on 52,000 volume with 5 trades. The average volume for the last 60 days is 151,285 and the stock's 52-week low/high is $0.025/$0.0941.


Know Labs, Inc. (KNWN)

High Rising Stocks, VentureLine, Stockwatch, Amigo Bulls, Dividend Investor, OTC Markets, Spotlight Growth, Insider Tracking, Stockhouse, Business Wire, 4-Traders, Open Insider, Marketbeat, last10k, Stockwatch, MarketWatch, Simply Wall St, Stockopedia, Investors Hangout, TradingView, Insider Monkey, InvestorsHub, Street Insider, Wallet Investor, and YCharts reported on Know Labs, Inc. (KNWN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Know Labs, Inc. is developing a new technology platform that measures blood glucose non-invasively. The Company invented a pioneering technology called Bio-RFID, which will provide information to consumers about their health and wellness. In addition, Know Labs uses its proprietary ChromaID technology to identify unique molecular signatures in materials.

The Company previously went by the name Visualant, Incorporated. It changed its name to Know Labs, Inc. in May of this year. Know Labs lists on the OTC Markets Group’s OTCQB.

Know Labs develops technology platforms that harness light and radio waves to uncover distinctive insights about the world. Its technology directs electromagnetic energy via a substance or material to capture a unique molecular signature.

Know Labs refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio- RFID are used to identify, detect, or diagnose substance markers or biomarkers, which may be invisible to the human eye.

ChromaID and Bio-RFID scanner modules can be integrated into an array of mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only formerly be performed by invasive and/or large and expensive lab-based tests.

In late May, Know Labs announced that Mr. Michael Grabham was appointed Chief Business Officer of the Company. Mr. Grabham is a Seattle serial entrepreneur. He has started six companies over the past 25 years. Mr. Grabham has led, as President, a number of companies from a regional telecommunications company ($14M annual sales) to a software assessment company (startup).

Last week, Know Labs released a video of the Company’s invention of a new technology to detect blood glucose non-invasively. In the video, Know Labs’ Chief Executive Officer, Mr. Phil Bosua, briefly talks about the breakthrough.

Know Labs is continually researching to expand the use of its technology into applications that will benefit everyday life. At present, Know Labs has 12 issued patents with 20 pending, covering its specialty.

Know Labs, Inc. (KNWN), closed Monday's trading session at $3.20, up 18.52%, on 86,233 volume with 281 trades. The average volume for the last 60 days is 22,112 and the stock's 52-week low/high is $0.1089/$3.15.


Pacific Health Care Organization, Inc. (PFHO)

NetworkNewsWire, Amigo Bulls, Zacks, OTC Markets, The Street, Stockopedia, Simply Wall St, MarketWatch, Morningstar, Stockhouse, Market Exclusive, 4-Traders, InvestorsHub, last10k, CapitalCube, Business Insider, Infront Analytics, TradingView, Insider Tracking, Insider Monkey, Marketbeat, GuruFocus, and Information Vine reported on Pacific Health Care Organization, Inc. (PFHO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Pacific Health Care Organization, Inc. via its subsidiaries, engages in managing and administering health care organizations (HCOs) and managed provider networks in the State of California. The Company specializes in workers’ compensation cost containment. Through its two HCOs, it offers injured workers a choice of enrolling in an HCO with a network managed by primary care providers requiring a referral to specialists; or a second HCO, where injured workers do not need any previous authorization to be seen and treated by specialists.

Incorporated in 1970, Pacific Health Care Organization has its head office in Newport Beach, California. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Pacific Health Care’s business goal is to deliver value to its clients that lessens their workers’ compensation related medical claims expense in a way that will assure that injured employees receive high quality healthcare, which allows them to recover from injury and return to gainful employment without excessive delay.

By way of its wholly-owned subsidiaries, the Company provides a range of effective workers’ compensation cost containment services. These include but are not limited to, Health Care Organizations, Medical Provider Networks, HCO + MPN, Workers’ Compensation Carve-Outs, Utilization Review, Medical Bill Review, Nurse Case Management, Lien Representation, Legal Support and Medicare Set Aside services.

Pacific Health Care Organization’s subsidiaries are Medex Health Care, Medex Managed Care, Medex Medical Management, Medex Legal Support, and IRC Industrial Resolutions Coalition.

In May, Pacific Health Care Organization reported financial results for the quarter ended March 31, 2018. It reported Total Revenue of $1,583,309 for the quarter ended March 31, 2018, versus Total Revenue of $1,541,256 for the quarter ended March 31, 2017.

Pacific Health Care reported Net Income of $399,681 or $0.12 per basic shares and $0.11 per fully diluted shares for Q1 2018, versus Net Income of $222,257 or $0.07 per basic and fully diluted shares for Q1 2017.

Pacific Health Care Organization, Inc. (PFHO), closed Monday's trading session at $5.60, even for the day. The average volume for the last 60 days is 1,225 and the stock's 52-week low/high is $3.075/$5.95.


The QualityStocks Company Corner

QMC Quantum Minerals Corp. (TSX-V: QMC) (FSE: 3LQ) (OTC: QMCQF)

The QualityStocks Daily Newsletter would like to spotlight QMC Quantum Minerals Corp. (QMCQF).

Testing is currently ongoing at QMC Quantum Minerals’ (TSX.V: QMC) (OTC: QMCQF) (FSE: 3LQ) Irgon Pegmatite Dike, which is estimated to contain more than 1.2 million tons of spodumene-bearing pegmatite which graded at 1.51 percent lithium oxide. To view the full article, visit:

QMC Quantum Minerals Corp. (TSX-V: QMC) (FSE: 3LQ) (OTC: QMCQF) is a British Columbia based company engaged in the business of acquisition, exploration and development of natural resource properties. QMC’s focus is on creating shareholder value through strategic acquisition and development of high quality lithium, silver, gold, nickel, copper and zinc prospects.

QMC’s current properties are in the Canadian province of Manitoba, one of Canada’s most productive, centrally located mining regions. These resources include the Irgon Lithium Mine project and two Volcanic Massive Sulphide (“VMS”) properties – the Rocky Lake and Rocky-Namew known collectively as the Namew Lake District Project – which contain base metal-rich mineral deposits. Excellent access and well-developed mining infrastructure to the company’s wholly-owned Irgon Lithium Mine Project offers significant value and ramps up the near-term production schedule, putting QMC in a position to take advantage of rising lithium prices.

The region’s historic resource estimate of lithium is well documented in a 1956 Assessment Report developed by a previous owner, Lithium Corporation of Canada Ltd. The project’s historical resource estimate of 1.2 million tons grading 1.51% lithium-oxide over a strike length of 365 meters and to a depth of 213 meters is being updated by QMC through a detailed channel sampling and subsequent drill program.

North Face Software Ltd. recently created an interactive 3-D model of the Irgon Dike utilizing all historical data derived from past drilling and underground work. The 3-D model clearly demonstrates that exploration and underground development has only taken place on the central portion of the dike, leaving significant potential to quickly increase tonnage.

The company’s latest assay results, obtained from 144 channel samples at QMC’s Irgon Lithium Mine Project, provided encouraging and positive results that compare favorably with the historic assays. QMC has received a drill permit from the Sustainable Development Office of the Manitoba government and is in the process of requesting and assessing bids from drilling contractors. The company plans to begin a 2,000-meter drill program to confirm the historic lithium oxide assay results documented in the historic 1953-54 drill program.

QMC’s experienced leadership team includes specialists in mineral exploration, geology, engineering, new business development, marketing and investor relations. The company’s team of qualified advisors includes consultant Bruce E. Goad, P.Geo., who has 40 years of experience in mineral exploration in Canada, Argentina, Asia and Africa. As a Qualified Person, Goad has worked on numerous deposit styles including rare element pegmatites, porphyry, banded iron formation (BIF) gold deposits, skarn, greisens,  and VMS. He has a wide and varied skill set which includes precious, base, industrial and rare metal projects with a sharp focus on gold exploration. Goad is the author of several scholarly publications on pegmatite granites of the southeastern Manitoba region.

The market for lithium has surged over the past three years with prices per metric ton tripling. The world’s rising demand for portable power can easily been seen in the electric vehicle and mobile device industries – both of which use lithium-based, renewable batteries as a power resource. QMC’s high potential prospects and experienced management team, both in geology and corporate finance, put QMC and its shareholders in an excellent position to take advantage of the lithium, precious and base metals markets.

QMC Quantum Minerals Corp. (QMCQF), closed the day's trading session at $0.3071, up 2.92%, on 117,515 volume with 38 trades. The average volume for the last 60 days is 115,927 and the stock's 52-week low/high is $0.078/$1.46.

Recent News


Consorteum Holdings, Inc. (OTC: CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH).

A holistic approach is necessary for ensuring that mobile connectivity, secure transactional processing and social connectivity are optimized for users throughout different markets. Consorteum Holdings, Inc. (OTC: CSRH), a software development and mobile solutions company, has spent the last several years developing relationships and licensing agreements that will enable it to participate in the rapidly developing fintech market and its associated verticals, providing secure mobile content and connectivity to a variety of end users.

Consorteum Holdings, Inc. (OTC: CSRH) is a software development and mobile solutions company focused on the delivery of digital offerings to mobile devices. The company provides mobile offerings, delivery of mobile content, mobile payments solutions and products through a mix of direct offerings, partnerships, license agreements and joint venture arrangements. A multi-year transition from a transaction management company focused on transaction processing solutions and products for the payment processing and financial transaction markets to multiple business verticals deepens the company’s commitment to deliver innovating solutions to end users who are using smart handset devices in radical new ways.

Consorteum Holdings, utilizing its Universal Mobile Interface™ (“UMI”) solution, offers opportunities in numerous markets with its capacity to support fully regulated, regionally compliant financial and social transactions via web and mobile. The company’s UMI technology has the capacity to provide solutions in FinTech, data analytics, secure payment processing, compliance lead transaction management and various digital social event sectors. The UMI platform allows cross operating system development to support all mobile devices while addressing the complex and highly regulated needs of the mobile FinTech industry.

Led by the development team at Consorteum’s wholly owned subsidiary 359 Mobile Inc., the Company has created an end-to-end FinTech solution utilizing the company’s UMI technology platform. Current mobile application and transaction solutions are plagued by poor experiences. Because UMI’s technology platform is designed to work across innovative payment, experience and product solutions, 359 Mobile believes there are both direct and partnership opportunities for the 359 Mobile UMI solution.

Consorteum’s primary sales and marketing strategy is focused on enabling and delivering solutions to the global mobile FinTech market with an emphasis initially on mobile gaming. The trend towards increased mobile gambling supports the need for a mobile platform such as the UMI to meet existing and new compliance regulations for the online gambling industry. The online gambling market is projected to double to nearly $1 trillion by 2021, according to a study by Juniper Research, with the majority of growth in this sector attributed to mobile devices. Consorteum’s management team believes there are fresh opportunities in this sector such as Mobile Marketing Services providing one-to-one marketing experiences for consumers; offering real-time services to Mobile Sports Book operators; and providing fixed odds betting solutions as well as social-based transactional solutions.

Consorteum’s management team includes Chairman and CEO Craig A. Fielding, a co-founder of the company with extensive experience in technology, programming and large system building; and Chief Operating Officer Patrick Shuster, who has over 25 years of business experience in sales, engineering, operations and marketing for the telecommunications industry. They are joined by John Osborne, SVP of Technology of ThreeFiftyNine Inc., an innovator in embedded systems hardware and software design; Patrick Doran, SVP of business development and marketing with over 30 years of diversified experience in major corporations as well as early stage companies; and Glenn Charlesworth, VP of Accounting, a seasoned executive with a solid track record in financial reporting, strategic planning, general management and operations, finance, start-up situations, and cash flow challenged operations.

Consorteum Holdings is committed to bridging the mobile divide by providing mobile connectivity, secure transactional processing and social connectivity solutions for both cloud and hosted based offerings in multiple business sectors.

Consorteum Holdings, Inc. (CSRH), closed the day's trading session at $0.0018, even for the day. The average volume for the last 60 days is 9,141,968 and the stock's 52-week low/high is $0.0005/$0.0085.

Recent News


Zenergy Brands, Inc. (OTC: ZNGY)

The QualityStocks Daily Newsletter would like to spotlight Zenergy Brands, Inc. (ZNGY).

Next-generation energy and technology company Zenergy Brands (OTC: ZNGY) is enabling commercial, industrial and municipal customers to reduce their carbon footprint and take control of their utility consumption. To view the full article, visit:

Zenergy Brands, Inc. (OTC: ZNGY) is the nation’s leading next-generation energy and technology company operating in the emerging smart energy, conservation, and utility industries. Headquartered in Texas, Zenergy provides an entire suite of conservation-based products and services that enable clients to achieve sustainability goals, reduce carbon emissions and improve their bottom line. The company’s cutting-edge Zero Cost Program™ reduces utility expenses by 20 percent to 60 percent by offering energy conservation, smart controls, and efficiency-based products and services to residential, commercial, industrial and municipal end-use customers.

The Zero Cost Program™ is a financing mechanism that allows customers to reduce water, natural gas and electricity expenses by implementing proven conservation technologies at no out-of-pocket cost. The Zero Cost Program™ enriches businesses by immediately reducing energy consumption through the use of smart controls, building automation, LED lighting solutions, refrigeration optimization, efficient water systems, EC motor controls, demand-side management and load factor correction.

A unique Managed Energy Services Agreement (“MESA”) allows a portion of these utility savings to be retained by Zenergy’s partner financing the upgraded, retrofit equipment and installation costs until a specified repayment period ends. After that, clients reap all the financial rewards of the technologies implemented, which Zenergy estimates should range between 25 percent and 45 percent of total utility costs.

Residential customers seeking cost-effective energy savings can also choose from a suite of “Smart Home” products including home automation, security monitoring, and energy conservation services that can be controlled 24/7 from the comfort and convenience of their smartphones or internet-connected smart devices. Zenergy’s residential program offers partnership opportunities for homebuilders and residential, multi-family real estate developers to provide smart home technologies to high-end customers.

Zenergy Brands’ acquisition of Enertrade Electric LLC, a fully operating, licensed Texas-based Retail Electric Provider (REP), further increases the company’s value proposition. Zenergy CEO Alex Rodriguez said this new subsidiary adds an essential complementary service to the company’s suite of smart energy products and services.

“Since our founding, our vision has been to converge smart controls (home and building automation) with energy conservation and retail energy to deliver the comprehensive smart energy service to customers,” Rodriguez said.

On a global scale, residential and commercial buildings account for nearly 45 percent of the world’s total energy consumption. Improving the energy efficiency of these homes and buildings is often a more affordable way to reduce harmful gas emissions while minimizing the need for new energy production. According to Navigant Research, global revenue for energy-efficient commercial building retrofits alone is expected to grow from $71.4 billion in 2016 to $100.8 billion in 2025. At the same time, the energy-efficient devices market is expected to reach a market size of $908 billion by 2022. Increasing demands for reduction in energy consumption and greenhouse gas emissions along with concerns over climate change are contributing factors driving the market’s overall growth.

Zenergy Brands, Inc. (ZNGY), closed the day's trading session at $0.0014, off by 6.67%, on 12,710,500 volume with 23 trades. The average volume for the last 60 days is 12,993,217 and the stock's 52-week low/high is $0.0014/$0.03.

Recent News


Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings Inc. (CHOOF).

Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Choom Hldgs Inc. (OTCQB: CHOOF), a company that is focused on delivering an elevated customer experience through its curated retail environments, high-grade handcrafted Cannabis supply, and a diversity of brands for the Canadian recreational consumer.

Choom Holdings Inc. (OTCQB: CHOOF) (CSE: CHOO) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s “Choom Gang,” a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with “choom,” the local’s term for marijuana. Choom’s trademark slogans pivot off another unconventional phrase (“Say Hello to…”), bringing a heady dose of good times and good friends together as the company invites investors to “Say Hello to Choom™” as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company’s first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom’s initial license applications to ensure the company’s readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company’s character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1’s revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic “Aloha” vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company’s growth strategy. Get ready to “Say Hello” to opportunity, good times and good friends with Choom™.

Choom Holdings Inc. (CHOOF), closed the day's trading session at $1.01, off by 1.94%, on 374,220 volume with 227 trades. The average volume for the last 60 days is 597,788 and the stock's 52-week low/high is $0.18/$1.129.

Recent News


Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF).

With full-on oil production scheduled to begin by the end of July, Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) (FRANKFURT: A2DYWC) has issued an update for investors on the latest developments at its Asphalt Ridge oil extraction facility, as well as other company operations.

Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is focused on oil and gas exploration and production on mineral leases it owns in Texas with Accord GR Energy Inc. and in expanding production capacity at its Asphalt Ridge heavy oil extraction facility in Utah.

Petroteq Energy is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry through the development of PetroBLOQ, the Company’s collaboration formed with First Bitcoin Capital Corp. (OTC: BITCF). PetroBLOQ’s novel blockchain-based oil and gas supply chain management platform is currently being co-developed by the two companies.

PetroBLOQ recently joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative. Membership with the 200-member EEA represents a wide variety of industries and offers 14 industry-focused, member-driven working groups.

“Joining this community of forward-looking enterprises and blockchain innovators is an important step for PetroBLOQ as we develop transformative solutions for the oil and gas industry,” said Petroteq Energy CEO Alex Blyumkin.

In addition, Petroteq has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry. “API has led the development of operating standards for our industry, and we look forward to contributing our experience with oilfield technologies in addition to introducing our PetroBLOQ platform to its members throughout the supply chain,” Blyumkin previously stated.

Petroteq Energy’s patent-pending application is a closed-loop, solvent-based process, which results in significantly lower per-barrel production costs than those incurred with traditional hot water-based oil sands extraction technologies. This green technology utilizes a small, modular footprint, produces no greenhouse gases, requires no high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits located around the world.

The Company’s Asphalt Ridge mineral lease on 3,000-plus acres in northeastern Utah features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent. In 2015, the company produced 10,000 barrels of oil from the Utah location and plans to increase production are underway. Utah holds over 32 billion barrels of undeveloped oil sands resources, which are also known as “oil-wet” deposits containing a mixture of sand and a dense, extremely viscous form of petroleum referred to as bitumen or tar. A recent upswing in developing domestic energy sources has intensified interest in technological advances such as Petroteq’s Liquid Extraction System.

The company’s Texas location includes an ownership interest (46%) in 7,000 acres under mineral leases with Accord, a Houston-based oil and gas exploration company that focuses on the development and recovery of heavy oil reserves and deposits. Two enhanced, licensed oil recovery technologies designed to increase oil recovery from more than 80 shallow oil wells on the property are expected to substantially improve the recovery rates of heavy oil deposits in this area. In both the Utah oil sands and traditional oil patch Texas project, the Company, its subsidiaries and Accord are using proprietary technologies, processes and methodologies to recover heavy oil, providing a distinct, strategic economic advantage for Petroteq Energy and its shareholders.

The Company continues to evaluate the development of other medium to heavy oil exploration, production and recovery projects on a global basis through a variety of structured agreements. These opportunities or other arrangements with private and governmental entities that utilize Petroteq Energy’s proprietary licensed technologies are expected to generate a significant return on investment.

The Company’s management team, board of directors and officers form an invaluable cross-section of industry leaders with extensive experience ranging from chemical engineering and solvent research, business development, international project management, entrepreneurial achievements, and senior management for global energy companies in North America and the Middle East. This impressive knowledge base covers both conventional and unconventional oil and gas projects and production, both in upstream and downstream industry sectors.

Petroteq Energy Inc. (PQEFF), closed the day's trading session at $1.08, up 1.13%, on 393,321 volume with 317 trades. The average volume for the last 60 days is 162,803 and the stock's 52-week low/high is $0.28/$1.8892.

Recent News


Marijuana Company of America Inc. (OTC: MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Following the passage of the 2018 Farm Bill in Congress, a conference committee has now been charged with finalizing the bill, which must be completed before the current legislation expires on September 30 ( This groundbreaking legislation is highly anticipated by many in the hemp industry, from growers and cultivators to manufacturers and producers of hemp plant-based products. Marijuana Company of America Inc. (OTC: MCOA) is one of the companies paying close attention as the bill progresses through committee.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.03045, off by 6.74%, on 5,452,576 volume with 234 trades. The average volume for the last 60 days is 7,350,742 and the stock's 52-week low/high is $0.021/$0.0728.

Recent News


First Cobalt Corp. (TSX-V: FCC) (OTCQX: FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF).

Cobalt exploration and development company First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) recently reported encouraging drill assay results indicating near surface cobalt mineralization trends in the Kerr area within its Canadian Cobalt Camp location. Trent Mell, president and CEO of First Cobalt, noted that results retrieved from the first six holes of 15 drilled along the strike extent of the historic Kerr Lake and Drummond Mines, where several silver veins are known to occur, reflect cobalt-silver mineralization as closely spaced veins.

First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance.

First Cobalt Corp. (FTSSF), closed the day's trading session at $0.31, off by 6.17%, on 138,052 volume with 64 trades. The average volume for the last 60 days is 192,882 and the stock's 52-week low/high is $0.2644/$1.3041.

Recent News


Medical Cannabis Payment Solutions (OTC: REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG).

Medical Cannabis Payment Solutions (REFG), a leader in technological solutions for the medical cannabis industry, announced today the company has added Mike Haridopolos, the former president of the Florida State Senate, to the company’s advisory board. Haridopolos joins former Oregon State Sen.

Medical Cannabis Payment Solutions (OTC: REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company’s state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company’s unique “StateSourced” proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven’t been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin’s cryptocurrency ($Weed) with Medical Cannabis Payment Solutions’ StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

“We’ve completed our transition from development stage to revenue stage,” says Roberts. “We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases.”

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry.

Medical Cannabis Payment Solutions (REFG), closed the day's trading session at $0.04, off by 9.60%, on 251,613 volume with 37 trades. The average volume for the last 60 days is 550,064 and the stock's 52-week low/high is $0.0161/$0.092.

Recent News


PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) expects to make promising progress in the research and development of a number of exciting products in 2018, according to the company’s chairman, CEO and President Stephen Van Deventer in an audio interview (

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.033, off by 13.16%, on 1,865,298 volume with 180 trades. The average volume for the last 60 days is 378,670 and the stock's 52-week low/high is $0.002/$0.20.

Recent News



The QualityStocks Daily Newsletter would like to spotlight GTX Corp (GTXOD).

GPS technology-focused holding company GTX Corp (OTC: GTXOD) this morning announced the completion of several corporate initiatives, including its securement of a million dollar round of financing at a 10x valuation of its current trading price. To view the full press release, visit:

GTX Corp (OTC: GTXOD) designs, manufactures and commercializes various products and services in the GPS tracking and monitoring business.  Operating domestically and internationally, via two subsidiaries engaged in the internet of things (IoT) and wearable technology industry. Founded in 2002 and headquartered in Los Angeles, California, the company is a pioneer in Smart GPS, cellular and Bluetooth Low Energy (BLE) tracking technology, offering complete, end-to-end tracking solutions through a proprietary IoT enterprise monitoring platform – the IoT Machine to Machine platform – backed by state-of-the-art hardware, software and connectivity solutions, patents and software algorithms.

Operating under the motto “We Put the ‘Where’ in Wearable Tech,” GTX’s main goal is to keep its customers connected to who and what matters most, with each of its patented tracking technologies providing real-time location coordinates on a map via a personalized portal. The company prides itself on offering not only technologies, but also effective solutions that provide safety, security and peace of mind by helping customers locate their loved ones or lost valuable items.

With a portfolio that includes more than 80 patents filed and issued and with products and services available in 35 countries, GTX’s tracking solutions use the latest in miniaturized, low-power GPS, mobile, RF and BLE technology, that can integrate seamlessly with multiple consumer products, enterprise and military applications. The company became a U.S. Military contractor in 2017 and is already developing asset and human tracking technology for the U.S. Air Force. Its list of customers also includes public health authorities and municipalities, emergency and law enforcement, NGOs, private companies, public and private senior care homes, and consumers.

The company’s flagship product is the award-winning GPS SmartSole®, the world’s first invisible wearable tracking device created specifically for people at risk of wandering, becoming lost or disoriented, including patients with Alzheimer’s, autism, dementia, traumatic brain injury and other cognitive problems. According to the World Alzheimer Report 2013 (, there are more than 100 million people worldwide who need constant care and monitoring because of a cognitive disorder, and their number is expected to rise to 277 million by 2050. Due to its hidden location – inside a shoe insert, the device can also be used by people undercover or at risk of kidnapping, such as government agents, military personnel, law enforcement, journalists, corporate executives, etc.

Other tracking devices designed and commercialized by the company for civilian or military use include:

  • Take-Along Tracker 3G: A powerful mini-tracking device with GPS, 2G and 3G GSM data and voice capabilities, as well as a motion sensor and sleep mode. The device can be easily attached to a keychain, lanyard, dog collar, pocket, bag or plush toy for a discreet but advanced tracking solution.
  • Invisabelt: Designed for children, this slim GPS tracker hidden inside a small waistband belt has a battery life of up to two days and is a great solution for parents who want to monitor their children’s location at all times.
  • Track My Workforce: An easy and cost-effective solution that allows businesses to track and monitor their mobile workforce. The app is available for both Android and iOS systems, and allows employers to monitor their workforce from a single company account.
  • E.T.S. -Personnel Equipment Tracking System: Currently in use at the Edwards Air Force Base, this tracking system allows real-time monitoring and surveillance of personnel and assets and has a 200+ square mile coverage. Solar powering capabilities and extend battery life allow the tracker to be used in areas without existing power sources.
  • GPS Rifle Tracker: The company’s smallest GPS tracker, designed to withstand shocks and water submersion due to its robust, military standard enclosure, can be mounted on any AR15 platform picatinny rail to detect weapon discharge, track weapons and inventory, and send time and location alerts.

Led by a management team with solid experience in wearable technology, IoT, consumer electronics, mobile and technology licensing, as well as finance and the footwear industry, GTX plans to leverage its core technology platform to reach new verticals via licensing agreements and strategic partnerships, and to monetize its intellectual property portfolio. The monetization campaign kicked off in 2017 has already identified 100 companies that could become licensees. Besides military and law enforcement, the company also eyes the biometrics market, home health, medicare and insurance and other security applications for potential uses of its IoT platform and tracking technology.

GTX currently has 15 domestic and international distributors, subscribers in 35 countries and more than 700 online affiliates. With multiple revenue streams, several consecutive years of double-digit revenue growth and a strong pipeline of lucrative commercial products, GTX is uniquely positioned to become a leading provider of tracking solutions on this growing multi-billion-dollar market.

GTX Corp (GTXOD), closed the day's trading session at $0.12, off by 33.15%, on 237,062 volume with 45 trades. The average volume for the last 60 days is 545,945 and the stock's 52-week low/high is $0.13/$0.20.

Recent News


Aftermaster, Inc. (OTCQB: AFTM)

The QualityStocks Daily Newsletter would like to spotlight Aftermaster, Inc. (AFTM).

Aftermaster, Inc. (OTCQB: AFTM), with offices in Scottsdale, Arizona, and Hollywood California, is an award-winning, leading-edge audio technology company that specializes in the development of proprietary and groundbreaking audio technologies and products. The company also operates world-class mastering and recording studios located in the heart of Hollywood, California, in the famous Crossroads of the World complex along Sunset Boulevard.

Aftermaster and its subsidiaries are engaged in the development and commercialization of proprietary (patents issued and pending), leading-edge audio and video technologies for professional and consumer use including the award-winning AfterMaster® audio technology, ProMaster™ and Aftermaster Pro™. Aftermaster is unique in the audio world because its team has produced, engineered and mastered more hit records than any audio company in the world. The Aftermaster team knows what sounds right and the Company holds a unique position in the world of audio technology.

The Company’s underlying technology, Aftermaster audio, delivers an audio experience unrivaled by any audio company. It brings an unprecedented new quality level to consumer audio by offering unparalleled clarity, depth, fullness and a significant volume increase to audio recordings without distortion or altering the original recording. Its versatility and smart processing characteristics make it effective across a broad range of applications from consumer electronics to industrial applications.

The Company also operates Aftermaster Recording and Mastering Studios which include the renovated production facilities of legendary director Alfred Hitchcock and the iconic recording studios of Crosby, Stills and Nash.

Aftermaster Labs maintains five primary business units: Aftermaster proprietary semiconductor chip and software for OEM licensing, proprietary consumer electronics, professional music mastering, online mastering, recording and mixing at its Aftermaster Recording and Master Studios, and Audio Consulting services. The Aftermaster semiconductor chip and software is used for embedding in consumer products, Aftermaster-developed and branded consumer and professional electronic products, ProMaster on-line music mastering for independent music artists and in-studio professional music mastering services.

Aftermaster has increasingly attracted interest from some of the music industry’s leading audio companies. A newly expanded partnership with TuneCore, the leading digital music distribution and publishing administration provider, gives TuneCore members access to Promaster through its instant mastering service which offers audio mastering of unparalleled quality at the click of a button. The Company also recently entered into a licensing agreement with Muzik headphones for use of its Aftermaster chip in their new headphone line.

The company’s first groundbreaking consumer product – the Aftermaster Pro – is designed to solve the universally widespread problem of poor, variable audio levels of television audio. Aftermaster Pro, which is smaller than an iPhone, masters and remasters inconsistent TV audio in real-time, creating an audio experience that offers clear, full-bodied depths of sound and most importantly, overall balanced audio. The Aftermaster Pro virtually eliminates the need to adjust TV volume to hear dialogue or to reduce the level of loud special effects. The Aftermaster Pro sells for $179 and is enjoying strong growth in sales to over 65 countries.

With the Company’s Promaster, state-of-the-art proprietary algorithms, artists receive four CD quality mastered versions of their track including “Powerful,” “Radio Ready,” “Bass Enhanced,” and “Vocal Enhanced.”  TuneCore artists have access to exclusive pricing on the Promaster pay-as-you-go instant mastering, as well as unlimited monthly and annual subscriptions. Aftermaster also holds a license agreement with headphone manufacturer, Muzik, Inc., for the use of Aftermaster’s patented audio remastering and audio enhancement technology.

Aftermaster won three Envisioneering Innovation and Design Awards at the 2016 Consumer Electronics Show in Las Vegas for both its Aftermaster TV device and its BelaSigna 300 processor semiconductor chip created through a partnership with ON Semiconductor. Aftermaster was also named an honoree for its ProMaster audio technology.

Aftermaster Audio Labs is led by a group of world-class audio engineers and music industry veterans who have been involved with the development and implementation of countless successful proprietary audio technologies and products.

The Team

Aftermaster co-founder and CEO Larry Ryckman is an award-winning entertainment and technology executive with over 25 years of achievements in the music and entertainment industries.

Shelly Yakus, co-founder and chief engineer at Aftermaster Audio Labs, is a renowned music producer, audio engineer/mixer and is widely considered the best engineer and mixer in the music industry.

Justin Timberlake, a Grammy and Emmy award-winning singer/songwriter/producer and actor, is a co-owner of Aftermaster Audio Labs, Inc. Timberlake is widely considered to be one of pop culture’s most influential entertainers in the world.

Peter Doell is one of the best-known mastering engineers in the world with over 35 years of experience mastering and engineering hundreds of chart-topping records, film scores and TV spots. Rodney Jerkins is an 8-time Grammy Award winning music producer/songwriter and considered to be one of the most influential and successful producers in the music industry.

Paul Wolff is a senior engineer and product development consultant at Aftermaster Audio Labs. Wolff has been involved in the professional music and audio industries as an audio engineer and product designer and manufacturer of professional audio products for more than 35 years.

Thousands of hours of testing millions of songs and audio sources of all types have been processed using Aftermaster’s award-winning technology and the results speak for themselves with platinum records, numerous strategic partnerships, and overwhelming industry support.

Aftermaster, Inc. (AFTM), closed the day's trading session at $0.035, even for the day, on 406,750 volume with 17 trades. The average volume for the last 60 days is 342,425 and the stock's 52-week low/high is $0.0345/$0.20.

Recent News



The QualityStocks Daily Newsletter would like to spotlight NUGL Inc. (NUGL).

NUGL Inc. (OTC: NUGL), is a search engine and online directory for the marijuana industry. NUGL’s database includes listings for dispensaries, strains, doctors, lawyers, service professionals, vape shops, hydro stores and brands. The company focuses on leading the evolution in business relations, development and organic data in the cannabis industry with metasearch technology.

Headquartered in Chino Hills, California, which is home to a projected $5 billion legal marijuana marketplace, NUGL is on track to become a major asset for the global cannabis industry and related services sectors. The company recently established a strategic partnership with Thinklogic and appointed CEO Chris Adams to NUGL’s growing board of directors. Thinklogic is a top-level software development company specializing in projects for start-ups to Fortune 500 companies.

“This strategic partnership puts NUGL in a distinguished class, adding a first-rate technical software expert like Chris gives NUGL a unique technological advantage,” said Brandon Vargas CEO of NUGL. “With the addition of Chris’s knowledge and expertise combined with Thinklogics’ experienced and skilled staff, NUGL will have the ability to evolve and build a strong infrastructure unmatched in the 420 industry.”

NUGL is nearing completion of its initial launch timeline, with plans to launch the app on both Android and iOS platforms within the next few weeks. NUGL’s live testing of its software includes enhanced reviews that detail up to 10 category ratings. Each of the category rankings allow users to leave comments and choose among a 5-star rating among all categories or as few as they wish. The software’s rating platform allows for customization and transparency for users while providing invaluable feedback to shops and professional services.

“This is a major feature that is critical to our community,” said Jeff Odle, NUGL’s CTO. “Enhanced ratings will be a definitive difference validating our organic listings and raising the standard for the industry. We want the users to know what they are getting before they step into a store or sign up for a service.”

Leadership Team

NUGL is growing its team of developers and launching new features on an ongoing basis. The company is ahead of an impressive timeline, which includes building blocks for scalability and massive growth.

“Everything we do is focused on user experience. Our philosophy is simple – make it fun and easy to use, with the purest and most unbiased results,” said Ryan Bartlette, NUGL CMO. “As the industry evolves and becomes more sophisticated, NUGL will adapt and build the best marketing technology for the cannabis-related companies. We have gotten in on the ground level and know the pulse of the industry.”

NUGL CEO Brandon Vargas is a founding member of G6 Management, a full-service consulting firm advising cannabis professionals in all aspects of business. With over 10 years’ experience in the cannabis space, he has worked on dispensary, cultivation and infusion entity formation, licensing, real estate acquisitions, construction and build out, marketing, policy and procedures, compliance, staffing, and capital raises. Vargas has an extensive background working with various medical marijuana companies on investment and in developing greenhouse and commercial cultivation, distillate for vapes cartridges, CBD oils and infusions.

CMO Ryan Bartlette is co-founder and CMO of 23Forty LLC and Boxy. He has expertly positioned and branded many companies while bringing them to market and is a sought out graphic artist, front-end developer, photographer, and visual artist with experience in the entertainment and technology industry.

Jeff Odle, NUGL CTO, is a successful senior software architect has a long and distinguished career developing some of the most innovative, cutting-edge platforms available. His unique and distinctive approach to creating the blueprint for advanced programming is industry leading and unprecedented. He is a top-level architect responsible for developing some of the most forward-­looking software for various industries.

NUGL’s board of directors includes John R. Armstrong, a founding partner of Horwitz + Armstrong, a full service general business firm handling all aspects of litigation and business strategy and advice. Armstrong and his partner, Lawrence Hortwitz, have more than 10 years of experience in the cannabis space, representing cannabis professionals in all aspects of business including business formation, licensing, compliance with local and state regulations, real estate acquisitions, corporate mergers and acquisitions, financing, inclusive of capital raises and alternative financing, contracts, and all forms of dispute resolution.

Board member Hendrik Klein, founder of Da Vinci Asset Management, a privately-owned investment firm, serves as CEO and executive board member of Fritz Nols AG, a capital marketing consulting firm specializing in trading and asset management. Klein has received several industry awards including the Austrian Hedge Fund Award, the German Hedge Fund Award, and most recently was named the Global Best Performing Systematic Quantitative CTA. Klein and the Da Vinci team employ the latest quantitative data research and analysis in their innovative investment strategy.

NUGL Inc. (NUGL), closed the day's trading session at $1.34, off by 1.47%, on 163,327 volume with 212 trades. The average volume for the last 60 days is 101,056 and the stock's 52-week low/high is $0.405/$1.80.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.